Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) ELISA Kits

CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Antibodies (61) and CYP2C9 Proteins (5) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
CYP2C9 1559 P11712
CYP2C9    
CYP2C9    
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top CYP2C9 ELISA Kits at antibodies-online.com

Showing 4 out of 26 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Human 5.8 pg/mL 23.5-1500 pg/mL Typical standard curve 96 Tests Log in to see 15 to 18 Days
$910.56
Details
Rat 0.124 ng/mL 0.31 ng/mL - 20 ng/mL 96 Tests Log in to see 13 to 16 Days
$880.00
Details
Eukaryotes
  100 Tests Log in to see 2 to 3 Days
$310.00
Details
Eukaryotes
  100 Tests Log in to see 2 to 3 Days
$385.00
Details

More ELISA Kits for CYP2C9 Interaction Partners

Human Cytochrome P450, Family 2, Subfamily C, Polypeptide 9 (CYP2C9) interaction partners

  1. The in vitro studies of Pristimerin (PTM) with CYP isoforms indicate that PTM has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4 and 2C9.

  2. Molecular dynamics simulations performed for the active species of the enzyme (heme in the Compound I state), in the apo or substrate-bound state, and binding energy analyses gave insights into altered protein structure and dynamics involved in the defective drug metabolism of human allelic variant CYP2C9*30 (A477T).

  3. Lower expression of CYP2C9 was associated with better overall survival and disease-free survival in Hepatocellular carcinoma tumor samples.

  4. In the villous trophoblast, CYP2C8 was the most abundant protein. Its expression is higher than the CYP2C9 and CYP2J2 in the cytotrophoblast in the embryonic stage of development and remains higher in syncytiotrophoblast of term placenta.

  5. A significant association between CYP2C9*3 and phenytoin-induced Stevens-Johnson syndrome was identified, especially in a Thai population (Meta-Analysis)

  6. In this study, we showed that patients with VKORC1-1639GA and CYP2C9*1/*1 alleles have lower sensitivity for warfarin than those with VKORC1-1639AA and CYP2C9*1/*1 alleles.

  7. Enzyme phenotyping with correlation analysis confirmed the predominant role of CYP2C9 in the biotransformation of siponimod and demonstrated the functional consequence of CYP2C9 genetic polymorphisms and fluconazole on siponimod metabolism.

  8. Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C19 = cytochrome P450 family 2 subfamily C member 19; CYP2D6 = cytochrome P450 family 2 subfamily D member 6)

  9. genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR = cytochrome p450 oxidoreductase)

  10. The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites.

  11. The final regression models for White and Black patients (Fig. 1) included age, weight, prosthetic valves, amiodarone use, CYP2C9*3, and VKORC1 3673 G>A genotypes as covariates, whereas possession of CYP2C9*2 and simvastatin use were retained in the final model for White, but not Black patients.

  12. The present study confirms the variable distribution of CYP2C8 (*2 and *3) and CYP2C9 (*2 and *3) allelic polymorphisms among South Indian diabetic populations.

  13. Our results further support a minor contribution of CYP2C9 genetic variability toward steady-state endoxifen concentrations. Integration of clinician and genetic variables into individualized tamoxifen dosing algorithms would marginally improve their accuracy and potentially enhance tamoxifen treatment outcomes.

  14. CYP2C9 genetic variation was associated with long-term overall mortality and non-major bleeding in elderly patients treated with vitamin K antagonists.

  15. Until the age of 19, weight has a far greater effect on Vitamin K antagonist dosing variation than VKORC1 and CYP2C9 polymorphisms. During the age of 20-40years, VKORC1 and CYP2C9 polymorphisms play a significant role.

  16. CYP2C9*3 did show significant effect on warfarin dose requirement

  17. Two SNPs in CYP2C9, rs2153628 and rs1799853 are associated with response to indomethacin for the treatment patent ductus arteriosus.

  18. the carriership of individual C and T alleles in the case of CYP2C9*2 gene, as well as A and C for CYP2C9*3 is not a predictor of antiretroviral drug-induced liver injury.

  19. Genetic polymorphisms in CYP2C9 cause significant interindividual variability in the metabolism of its substrates. This study estimated the coefficient of variation (CV) for the intrinsic hepatic clearance of tolbutamide by CYP2C9 for each CYP2C9 genotype using previously reported area under the blood concentration curve (AUC) and oral clearance (CLoral) values in a Monte Carlo simulation with a dispersion model.

  20. These results suggest that genetic polymorphisms of CYP2C9 enzymes result in the production of varying levels of biologically active JWH-018 metabolites in some individuals, offering a mechanistic explanation for the diverse clinical toxicity often observed following JWH-018 abuse.

CYP2C9 Antigen Profile

Antigen Summary

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Gene names and symbols associated with CYP2C9

  • cytochrome P450 family 2 subfamily C member 9 (CYP2C9) antibody
  • CPC9 antibody
  • CYP2C antibody
  • CYP2C10 antibody
  • CYPIIC9 antibody
  • P450IIC9 antibody

Protein level used designations for CYP2C9

cytochrome P-450 S-mephenytoin 4-hydroxylase , cytochrome P-450MP , cytochrome P450 2C9 , cytochrome P450 PB-1 , flavoprotein-linked monooxygenase , microsomal monooxygenase , xenobiotic monooxygenase

GENE ID SPECIES
1559 Homo sapiens
Selected quality suppliers for CYP2C9 (CYP2C9) ELISA Kits
Did you look for something else?